The questionnaires provided diagnostic information on broadly defined anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED) and recurrent self-induced purging in the absence of binge eating (EDNOS-P), along with self-reported use of medication six months before, during, and 0C6 months after pregnancy. Results The prevalence of eating disorder subtypes before and/or during pregnancy was: 0.09% AN (n = 54), 0.94% BN (n = 585), 0.10% EDNOS-P (n = 61) and 5.00% BED (n = 3104). reflux disease.(PDF) pone.0133045.s003.pdf (55K) GUID:?44ED0E90-4C5D-4367-9078-F42488328C90 S2 Table: Use of psychotropic medication subgroups before, during, and after pregnancy by type of eating disorder?. Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not normally specified, purging type), BED (binge-eating disorder), ED (eating disorder). ?The No eating disorder group is the reference group AZD9496 for all those analyses. *Indicates p-value 0.001; ?Indicates p-value 0.01.(PDF) pone.0133045.s004.pdf (70K) GUID:?BAAF56A4-325E-4760-9C15-8FA819C7DAD6 S3 Table: Use of gastrointestinal medication subgroups before, during, and after pregnancy by type of eating disorder?. Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not normally specified, purging type), BED (binge-eating disorder), ED (eating disorder); GERD: Gastroesophageal reflux disease. Drugs for GERD include H2-receptor antagonists, prostaglandins, proton pump inhibitors, and other drugs for GERD (i.e., sucralfate and alginic acid). ?The No eating disorder group is the reference group for all those analyses. *Indicates p-value 0.001; ?Indicates p-value 0.01.(PDF) pone.0133045.s005.pdf (71K) GUID:?ADE85FF7-584D-4762-B1BF-1257AD4D843D S4 Table: Use of any analgesic subgroups before, during, and after pregnancy by type of eating disorder?. Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not normally specified, purging type), BED (binge-eating disorder), ED (eating disorder), NSAIDs (nonsteroidal anti-inflammatory drugs). Antipyretics include acetylsalicylic acid, acetaminophen alone or as a combination product. ?The No eating disorder group is AZD9496 the reference group for all those analyses. AZD9496 *Indicates p-value 0.001; ?Indicates p-value 0.01.(PDF) pone.0133045.s006.pdf (72K) GUID:?D39BCBE3-6F6C-40EE-AF1D-320ABEC08F23 Data Availability StatementAll relevant data are within the paper and its Supporting Information files. Abstract Introduction Little is known about medication use among women with eating disorders in relation to pregnancy. Aims To explore patterns of and associations between use of psychotropic, AZD9496 gastrointestinal and analgesic medications and eating disorders in the period before, during and after pregnancy. Method This study is based on the Norwegian Mother and Child Cohort Study (MoBa). A total of 62,019 women, enrolled at approximately 17 weeks’ gestation, experienced valid data from your Norwegian Medical Birth Registry and completed three MoBa questionnaires. The questionnaires provided diagnostic information on broadly defined anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED) and recurrent self-induced purging in the absence of binge eating (EDNOS-P), along with self-reported use of medication six months before, during, and 0C6 months after pregnancy. Results The prevalence of eating disorder subtypes before and/or during pregnancy was: 0.09% AN (n = 54), 0.94% BN (n = 585), 0.10% EDNOS-P (n = 61) and 5.00% BED (n = 3104). The highest over-time prevalence of psychotropic use was within the AN (3.7C22.2%) and EDNOS-P (3.3C9.8%) groups. Compared to controls, BN was directly associated with incident use of psychotropics in pregnancy (adjusted RR: 2.25, 99% CI: 1.17C4.32). Having AN (adjusted RR: 5.11, 99% CI: 1.53C17.01) or EDNOS-P (adjusted RR: 6.77, 99% CI: 1.41C32.53) was directly associated with use of anxiolytics/sedatives postpartum. The estimates of use of analgesics (BED) and laxatives (all eating disorders subtypes) were high at all time periods investigated. Conclusions Use of psychotropic, gastrointestinal, and analgesic medications is considerable among women with eating disorders in the period around pregnancy. Female patients with eating disorders should receive evidence-based counseling about the risk of medication exposure versus the risk of untreated psychiatric illness during pregnancy and postpartum. Introduction Eating disorders are severe mental illnesses primarily affecting women of childbearing age. It is estimated that 0.9%, 1.5%, and 3.5% of the female population experience anorexia nervosa (AN), bulimia nervosa (BN), or binge eating disorder (BED), respectively, over the life time [1]. An active or past eating disorder does not preclude a woman from getting pregnant. Even women with AN, despite the high prevalence of menstrual disturbances (up to 90%), may become pregnant during an intermittent phase of regular ovulation, or during the first ovulation after a period of amenorrhea [2]. The fertility HK2 rate and parity among women with eating disorders is comparable to that observed in the general populace, although women with BN seem to undergo fertility treatments more frequently than healthy controls [3C5]. On the other hand, pregnancy is usually often unplanned among women suffering from AN [6]. During pregnancy, up to 7.5% of women may meet the diagnostic criteria for an eating disorder [7]. Eating disorders can negatively affect pregnancy.